Drugs / MIBG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01730417 | Nov 2009 → Jun 2011 | heart failure, neuroendocrine neoplasm | Bennett Chin | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02378428 | Mar 2014 → Dec 2025 overdue | neuroendocrine neoplasm | Nationwide Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIBG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02378428 ↗ |
| Known as | iobenguane | “The goal of this proposal is to produce and test high specific activity Ultratrace iobenguane I 123 in normal human volunteers.” NCT01730417 ↗ |
| Modality | Diagnostic / imaging agent | “The low specific activity iobenguane I 123 has been shown to be useful for the detection and staging of neuroendocrine tumors in adults and children and imaging neuronal...” NCT01730417 ↗ |